Searched for
LUPIN STOCK UPDATE
Pharma stocks in focus after medicine tariff changes in Union Budget 2025Finance Minister Sitharaman announced the inclusion of six life-saving drugs in the concessional 5% duty slab to enhance access to critical...- Here's why CA Rudramurthy BV is bullish on IRCTCDefinitely, yesterday there were very-very clear signs of pharma just shooting up and that is a clear indication that yes, most of the stoc...
- Time to buy pharma? 3 stocks Forum Parekh is betting onZydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life wil...
- Biocon, SAIL among 10 stocks with RSI trending downOn September 22, Friday, StockEdge identified 40 stocks with a declining Relative Strength Index (RSI). ETMarkets has chosen 10 of these st...
- Ajanta Pharma, Oil India and 8 other midcap stocks hit new 52-week high on ThursdayThe data was sourced from BSE at 1.15 pm, and the updates from the real-time data could come with a lag. The below data also pertains only ...
- Lupin, Glenmark Pharma, 7 BSE Healthcare stocks which hit 52-week high on WednesdayThe data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only ...
- SBI Life, Cipla among 5 BSE 100 stocks which hit new 52-week high on TuesdayTuesday, August 08, 2023, marked a remarkable day for the BSE 100 index as several key stocks surged to new 52-week highs, underscoring str...
- IRFC, Lupin among 7 midcap stocks which hit new 52-week high on MondayThe BSE MidCap index stocks reached new 52-week highs, reflecting robust market performance and investor optimism. Alkem Laboratories, Auro...
- BHEL, Tata Communications, 7 other counters touch new 52-week highBSE MidCap Index stocks achieved new 52-week highs on July 27. Leading the charge were Colgate-Palmolive and Lupin, alongside other promine...
- Coforge, Trent, PolicyBazaar among top 6 stocks in Nifty Midcap index which touched fresh 52-week highsSeveral stocks within the Nifty Midcap index reached new 52-week highs, indicating their potential for growth and generating enthusiasm amo...
- Market Movers: Lupin shares in delicate condition on margin squeezeLupin's EBITDA margins contracted by 580 bps quarter-on-quarter (QoQ) and 1,050 bps YoY at 9.9 per cent even as profit rose 24 per cent YoY
- Lupin Q2 results: Firms posts Rs 2,095 crore loss due to one-off impairmentsDuring the quarter, the company booked a provision of Rs 1879.6 crore towards litigation and settlement related to diabetic drug Glumetza c...
- Rakesh Jhunjhunwala, LIC hiked stake in this pharma company in Q2Total holdings of mutual fund houses in the company also increased to 12.58 per cent from 11.94 per cent on a quarter-on-quarter basis, dat...
- With several firms getting USFDA clearances, Street to breathe easy about pharma stocksLast week, Lupin, Cadila Healthcare and Alembic Pharma received clearances from the US regulator for their key facilities.
- Mapping the market: Oil stocks slide, telecoms out of coverage areaF&O turnover dropped, as was the activity in the cash market, as investors awaited fresh triggers in terms of earnings and progress of mons...
- Lupin shares surge 6%; mcap zooms Rs 4,440 croreThe stock surged 6.25 per cent to settle at Rs 1,657.30 on BSE. During the day, it climbed 8.72 per cent to Rs 1,695.95.
- Committed to close corrective action at Goa by December: LupinIt said that even if the US Food and Drug Administration decides to hold back approvals from the Goa facility it won't have much impact on ...
- Lupin nosedives 8% even as drugmaker reports 47% PAT growth in Q4The company had reported PAT of Rs 547 crore in the same quarter last financial year.
- Retail holdings show healthy rise between January and MarchRetail investors showed confidence in stock markets between January and March, a period that witnessed sharp swings.
- FDA nod for drugs crucial for Lupin, Dr Reddy’s LaboratoriesLupin posted its worst quarterly performance with a drop in growth in key markets like US and Japan, resulting in flat revenues and a 300-b...
Load More
